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Spec i a l  f ea t u r e
Traditional Chinese medicine (TCM, zhongyi)
(2)
refers to the Chinese medicine promoted by the
Chinese government since the 1950s, and does not
include all the remedies referred to as Chinese medicine in
the broadest sense. (3) It can be defined as neo-traditional
medicine, since elements of biology and modern medicine
play a significant part in its dissemination and practice. In
the 1990s, the increasing biomedicalisation of “traditional”
treatment was driven by two factors, that of the long-term
state policy of integrating Chinese and Western medicine
and modernising and normalising Chinese medicine, (4) and
that of forces arising from cultural and economic globalisa-
tion, as manifested in the circulation of scientific as well as
traditional ideas and practices around the world and in the
economic stakes crystallising around international health in
the context of a world market.
In the early twenty-first century, the traditional pharma-
copoeia (zhongyao) in its buoyant, state policy-supported
form, is tending toward becoming a pharmacotherapy
(zhongyiyao), and even a pharmacology of traditional medi-
cine (zhongyiyao xue).
Starting with the recognition that treatment and research in
traditional Chinese medicine are an integral part of the pub-
lic intervention plan for funding the treatment of
HIV/AIDS gradually implemented since 2004, I have fo-
cused on the modalities of utilisation and integration of this
body of knowledge and practice in the management of
AIDS, which I have researched in the context of previous
works on therapeutic plurality in China. My article is in two
parts, the first of which seeks to contextualise the subject in
the framework of the major realignment of health policies in
2004. The second part deals with the integration of TCM
in therapies and research on HIV. This process, in its con-
ceptual and operational modes, is concrete evidence of the
“biomedicalisation” of TCM that accelerated in the 1990s.
In the adaptation of existing and recommended treatments
on an international level, combined treatments in biomedi-
cine and TCM are the object of clinical research and prac-
tice. In biomedicine it is mainly a question of ARVs (anti-
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1. This research was carried in the framework of the IRD-PUMC/CAMS (Beijing Union
Medical College/Chinese Academy of Medical Sciences) Project, Social Science
Programme, with financial support from the CEFC, Hong Kong. The project was se-
lected in the framework of the call for research projects in 2006.
2. The terms xiyi (literally “Western medicine”) and zhongyi (literally Chinese medi-
cine”) are used by patients and therapists and in official terminology. I have cho-
sen to use the term TCM (traditional Chinese medicine), which is the official Eng-
lish translation in China of zhongyi, because my approach is from an insider’s view
(here, official Chinese), which is consistent with an anthropological perspective.
3. For example, local, popular, or family medical treatments (minjian yiliao, difang yil-
iao/liaofa, etc.), which are not necessarily part of the TCM corpus of practices and
treatments.
4. On the initial project of medicine integrated into the construction of a socialist so-
ciety, see Kim Taylor, Chinese Medicine in Early Communist China, 1945-1963: A
Medicine of Revolution, London, Routledge, 2005, 236 pp.; on the modernisation
and normalisation of Chinese medicine see Judith Farquhar, Knowing Practice: The
Clinical Encounter of Chinese Medicine, Boulder, Westview Press, 1994, 260 pp.;
on the construction of one standardised form among others, see Elisabeth Hsu, The
Transmission of Chinese Medicine, Cambridge UK, Cambridge University Press,
Cambridge Studies in Medical Anthropology, 1999, 296 pp., pp. 88-127.
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In the context of a social and medical response to AIDS at a national level recommended by the Chinese authorities,
the policy of eventual extension of treatment to all patients reveals “Chinese characteristics” that are akin to
international concerns regarding the use of alternative and complementary medicine. One concerns the use of
traditional Chinese medicine (TCM), principally in combined treatment (biomedicine with Chinese medicine) in a
public health system in which it plays a relatively large part compared to other health systems in the world. This
article focuses on the integration of TCM in therapies and research on HIV/AIDS.
Spec i a l  f ea t u r e
retrovirals) applied to AIDS and of other medicines recom-
mended in the treatment of the opportunist illnesses of
AIDS, and in TCM it is a matter of treating opportunist ill-
nesses or of developing complementary treatments that
might reduce the side effects associated with ARVs, as well
as stimulating the immune system, relieving pain, and work-
ing towards increased well-being and a better life for people
living with HIV/AIDS (PLWHA). This research aims to
adapt existing treatments and develop innovative treatments
designed within the protocols as possible substitutes for
ARVs. Based on analysis of a number of publications and
observations, I will give examples of clinical tests aimed at
the scientific certification of AIDS treatments in the wider
context of R&D in TCM.
It should be pointed out that public policy measures taken by
China and the long-term political intention to promote tradi-
tional medicine come up against the preoccupations of states
and civil and economic players on an international level, as
well as the WHO’s recommendation to integrate traditional
medicines in public health systems, promulgated at the Inter-
national Conference on Primary Health Care in Alma-Ata
back in 1978. At that time the Chinese system appeared to
be a model to be followed by other states, particularly those
with very limited medical resources, in view of the objective
of “Health for All in 2000.” The Beijing declaration
adopted at the end of the WHO First World Conference on
Traditional Medicine, held from 7-9 November 2008 in Bei-
jing, (5) is a continuation that calls for wider application of the
WHO public policy and strategy guidelines for traditional
medicine (2002-2005) initiated in 1978: “Recognizing the
progress of many governments to date in integrating tradi-
tional medicine into their national health systems, we call on
those who have not yet done so to take action.” It should be
added that the definition of “traditional medicines” is very
wide, including a range of therapies, practices, and knowl-
edge that is highly diverse, depending on country and local-
ity, and which can be termed “alternative medicines” or
“complementary medicines.” (6)Refo rm ula tio n of  na tiona lhea lt h p oli c ie s  a nd int egr ati onof  T CM  
Beginning in 2004, a new committee at State Council level
entrusted with controlling AIDS, aided by more effective
monitoring devices, has led to an improved understanding
of epidemic dynamics and responses. Knowledge and con-
trol of the epidemic have progressed considerably as a re-
sult, although many challenges and obstacles remain. Treat-
ment and follow-up of HIV/AIDS is being gradually ex-
tended throughout the country, according to the interna-
tional norms recommended by WHO for countries with
limited resources. For the central government, the chal-
lenge today is to implement these new policies in a rela-
tively homogenous fashion at the local level. It would be a
mistake, however, to overestimate the responsibility of
provincial governments or authorities lower down in the ad-
ministrative structure, who do not always have the human
and financial resources to apply these new measures cor-
rectly. (7) Disparities at the regional, administrative, and in-
stitutional level, as well as an enduring and widespread stig-
matisation of the epidemic and those infected or affected
by it, (8) constitute major obstacles to the effective applica-
tion of new public policies.
It should be mentioned that in December 2003, before the
implementation of the national HAART (Highly Active
Anti-retroviral Treatment) (9) programme that was in the
course of being elaborated, MSF had initiated a programme
of confidential treatment and follow-up for patients infected
by HIV in Nanning, the capital of Guangxi Province, in col-
laboration with the provincial CDC (fangyi ju) and the re-
gional Public Health Bureau (weisheng ju). This was a pilot
project in China at the time, and was considered a model to
be replicated in the official health structures specialising in
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5. Available online: http://www.who.int/medicines/areas/traditional/TRM_BeijingDeclara-
tionEN.pdf.
6. The concept of CAM (Complementary and Alternative Medicines) is widely used in med-
ical science, in public health, and in human and social health sciences, including all
therapies that do not originate in internationally standardised modern medicine or bio-
medicine. Such an all-encompassing definition means that it is usually discussed in
context in order to be operative rather than being reduced to a theoretical tool.
7. Source: field research carried out by the IRD-PUMC/CAMS research team in sites in the
provinces of Hainan and Henan.
8. On firsthand experiences of discrimination against patients with HIV relating to percep-
tions of AIDS, see Rachel Yunqiu Zhou, “‘If you get AIDS… you have to endure it alone’:
Understanding the social constructions of HIV/AIDS in China,” Social Science and Med-
icine, 2007, vol. 65, pp. 284-295; on discriminatory rumours, perceptions of AIDS and
the criminalisation of seropositive people in the media, see Jing Jun, “The Social Origin
of AIDS Panic in China,” in Joan Kaufman, Arthur Kleinman, Tony Saich (eds), AIDS and
Social Policy in China, Cambridge, MA, Harvard University Asia Center, 2006, 267 pp.,
pp. 152-169; on the phenomenon of stigmatisation at the beginning of the decade, see
Evelyne Micollier, “HIV/AIDS-related Stigmatization in Chinese Society: Bridging the Gap
between Official Responses and Civil Society,” in Alice Desclaux (ed.) HIV/AIDS Stigma
and Discrimination: An Anthropological Approach, Paris, UNESCO Publications, Study n°
20, pp. 33-46. On perceptions of AIDS in the context of Chinese cultures in 1990s, see
Evelyne Micollier “L’Autre: porteur originel et/ou vecteur privilégié du VIH/SIDA (Chine
populaire-Taiwan),” in Claude Fay (ed.), “Le sida des autres: constructions locales et in-
ternationales de la maladie,” Autrepart, 1999, n°12, pp. 73-86.
9. HAART refers to medicinal regimes combining ARVs to obtain optimal effectiveness; cf.
DHHS/Henry J.Kaiser Family Foundation Panel on Clinical Practices for the Treatment of
HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and
adolescents, October 2004 revision, //aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf.
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the treatment and follow-up of AIDS, such as the Number
8 Hospital in Guangzhou. (10)
In April 2004, the Ministry of Health, in cooperation with
Ministry of Finance and the SATCM (State Administration
of TCM, guojia zhongyiyao guanliju), (11) promulgated a se-
ries of recommendations aimed at the standardisation of
ARV treatments. The set of measures known as “Four Frees
and One Care” (simian yiguanhuai) includes free ARVs for
all patients resident in rural areas and for patients resident in
urban areas who face financial difficulties; free testing and
advisory services in high-prevalence areas; free education for
children orphaned by AIDS; free testing, advice, and
mother-to-child transmission prevention for pregnant women;
and financial support for seropositive patients whose finan-
cial resources are inadequate. (12)
Since the end of 2003, five ARVs (AZT, d4T, ddI, NVP, and
IDV) (13) have been produced by pharmaceutical companies
based in China, and two others (3TC, EFV) (14) have been im-
ported. These frontline ARV treatments prescribed in China in
the framework of the national programme correspond to the
norms recommended by the WHO for countries with limited
medical resources. A detailed manual has been drawn up to fa-
cilitate the implementation of the new policy of treatment and
extension of treatment. (15) At the same time, the government
has increased investment and development of research into pre-
ventive vaccines, ARVs, the adapting of ARVs to clinical prac-
tice, and TCM products. (16) A large-scale intervention and re-
search programme encourages provinces to test traditional med-
icine products for the treatment and follow-up of AIDS.
While estimates of the total number of patients benefiting
from the HAART treatment in the framework of the na-
tional programme vary according to the source and do not al-
ways include patients who are following an TCM treatment,
UNAIDS and international medical publications indicate
that around 20,450 patients received HAART treatment at
the end of 2005, 24,400 at the end of 2006, (17) and 32,000
at the end of 2007. (18) At the end of 2006 these included
more than 6,000 patients benefiting from a TCM treatment.
These data should be viewed with caution, as the figures vary
depending on the documents used. While the official rate of
the numbers of patients who withdrew from HAART treat-
ment was 8 percent and that of deaths among patients was
10 percent, (19) unofficial sources indicate that the combined
rate of withdrawal from treatment and death could reach 50
percent, depending on the locality and the population con-
cerned. On this question, our field data reveal contrasting sit-
uations depending on the location and the dominant means
of transmission among patients. For example, in Number 8
Hospital in Guangzhou, which specialises in treatment of
and research into infectious diseases and includes a treatment
department and an AIDS research centre, the combined loss
rate among patients on ARVs, a population with a majority
(90 percent) in an advanced symptomatic state (20) and made
up of intravenous drug users (70 percent), was around 10
percent in 2007, with a 6 percent death rate and 4 percent
rate of withdrawal from treatment. (21) According to our field
data, withdrawal behaviour is seen as widespread: some pa-
tients readily state that a third or half of patients decide to
“withdraw” from the medical treatments prescribed.
Observance and adherence to ARV treatment are crucial
both for effectiveness and in reducing resistance. (22) The
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10. Source: research carried out among the nursing team, clinicians, and researchers in
January 2008, and among members of local NGOs in January 2005, including AIDS Care
based in Guangzhou, which was recognised for its exemplary action in the 2000s. This
organisation was founded in 2002 by Thomas Cai, an activist who had the courage to
make public his HIV-positive status, and built a very good reputation among various
local national and international actors engaged in AIDS intervention in China. Thomas
Cai contributed to the reference work published in 2006 on AIDS and social policy in
China, edited by Joan Kaufman et al, op. cit., chap. 8, pp. 170-174.
11. The SATCM is an organisation that is part of the Ministry of Health (Weisheng bu). Its di-
rector general, Wang Guoqiang, is also Deputy Minister of Health.
12. Jennifer Pan, China National Free Antiretroviral Therapy Program, Beijing, Chinese Cen-
ter for Disease Control and Prevention, National Center for AIDS/STD Prevention and
Control, June 2005.
13. Respectively Zidovudine, Stavudine, Didonosine, Nevirapine, Indinavir.
14. Respectivement Lamivudine, Efavirenz.
15. China Free ART Manual, Chinese Center for Disease Control and Prevention (CDC), Jan-
uary 2005, 68 pp. We should note that a much more precise and complete revised edi-
tion, based on updated data, appeared in 2008, 212 pp.
16. On research and management of AIDS based on the adaptation of the biomedical model
rather than the traditional model, cf. Evelyne Micollier, “Facettes de la recherche médicale
et de la gestion du VIH-sida dans le système de santé chinois: un autre exemple d’adapta-
tion locale de la biomédecine,” Sciences Sociales et Santé, 2007, vol. 25, n°3, pp. 31-39.
17. Bates Gill, Susan Okie, “China and HIV—A Window of Opportunity,” New England Jour-
nal of Medicine, 2007, vol. 356, n°18, pp. 1801-1805.
18. Updated data from the 2007 report, Key Data UNAIDS, http://www.unaids.
org.cn/en/index/ page.asp?classname=Key+Data&id=178&class=2, consulted on 15
January 2009; including 6,000 in Yunnan, one of the regions most affected by the epi-
demic since its emergence, cf. Wang Jiang, Wang Yan, “6,000 AIDS patients in Yunnan
receive free treatment,” Xinhua, 30 November 2007. 
19. National Center for STD/AIDS Prevention and Control, unpublished report on ARV Treat-
ment Situation, June 2005.
20. Most of the patients received prior treatment for opportunist infections such as tuberculosis.
21. Field research carried out in January 2008 on the hospital site among the medical team;
context of data collection: working meetings where clinical practice, treatment, and follow-
up problems were discussed. Also taking part were members of the hospital management
and of the local nursing and research team, students in specialised medical training, and
two experts/researchers in HIV/AIDS, one an epidemiologist and the other an immunovi-
rologist on a mission from my laboratory IRD, UMR 145 “VIH et maladies associées.”
22. Observance refers to the following of treatment in reality, in an objective manner; ad-
herence refers more to the perceptions and representations of the patient concerning
his treatment and its effectiveness in their common meaning diverge from or converge
with medical or biological meaning. We should also point out that since 2006, a moni-
toring and control system has been established, cf. UNAIDS, A Joint Assessment of
HIV/AIDS Prevention, Treatment and Care in China (2007), State Council AIDS Working
Committee Office, UN Theme Group on AIDS in China, 1 December 2007, 38 pp., p. ii.
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problem of observance is emphasised by epidemiologists
and public health specialists, (23) who say that patients need
to be better informed and specific strategies should be devel-
oped for those with a very low level of education. The ad-
ministration or use of traditional medicines to treat HIV or
AIDS has not posed any significant problem, (24) these treat-
ments being generally better accepted by patients.
Lastly, in the framework of the new policies, new institutional
models piloted and supported by the SATCM are being set
up, bringing together research structures, hospitals, and univer-
sity training institutes. These include the AIDS research sec-
tion of the National Association of TCM in Zhengzhou, and
the AIDS research institute at the TCM University of Henan.
In Beijing, the organisational structure had been redesigned
previously: the traditional medicine organisations specialising
in the treatment and follow-up of AIDS include AIDS treat-
ment centres (aizibing liaofa zhongxin) such as that at the
Guang’anmen Hospital (GAMH AIDS Clinical Centre),
one of the hospitals of the National Academy of Chinese
Medical Sciences that works in collaboration with research
structures such as the AIDS department of the same Univer-
sity. In 2000, a clinical research department, an AIDS treat-
ment centre, and laboratories for testing, diagnosis, and analy-
sis of viral load, were set up within Guang’anmen Hospital.
Ext en s ion  of  tr ea tment  an d in tegr ati on  ofTCM i n th e  n ati on al  p lan :  A d iac h ro ni cper sp ec tive  a nd  th e p res en t  sit ua tion
Since the 1980s, the Chinese government has shown politi-
cal determination to enhance the value and explore the po-
tential contribution of TCM to the prevention, treatment, and
follow-up of AIDS. This determination has been further re-
inforced since the realignment of public policy in 2004: ac-
cording to Wen Jiabao, (25) “the objective is to develop inte-
grative methods of Chinese and Western medicine aimed at
treating AIDS, and to this end, the resources of TCM must
be completely exploited.” Deputy Prime Minister Wu Yi also
emphasised the importance of TCM during the National
Working Meeting of Prevention and Treatment of AIDS that
was held in the same year. We should note that the necessity
of developing integrated treatment through the contribution
of TCM was already indicated in official documents dealing
with controlling the AIDS epidemic at the end of the 1990s
and the beginning of the 2000s. (26) In real terms, the organ-
ising and coordinating group on the prevention and treatment
of AIDS was formed later in 2004 by the SATCM, drawing
up the first project for the development of TCM for the treat-
ment of AIDS (Project of AIDS Prevention and Treatment
with TCM of SATCM, 2004-2005). A series of public pol-
icy measures and regulations promulgated by the SATCM
and the Ministry of Health followed. (27)
In terms of research, before the discovery and marketing of
ARVs began in 1998, the Ministry of Science and Technol-
ogy (Keji bu) had in the 1980s identified the development
of TCM for the treatment of AIDS as a major project of
public research in biological and medical science. In fact,
clinical trials of treatment of AIDS with TCM were carried
out in Tanzania in 1987: a group of researchers from the Na-
tional TCM Research Institute, an academic institution that
has since been raised to the status of an academy and re-
named National TCM Academy in Beijing, then headed by
Lu Weibo, director of the institute’s AIDS department, was
sent to Tanzania, where Chinese medicine was already
widespread and appreciated, (28) to conduct exploratory re-
search. The official explanation for the delocalisation of this
research cited the fact that the pool of patients identified in
China was too small to satisfy the criteria for inclusion in a
test. These studies were carried out until 1995, with the re-
sults reported in a number of publications. (29) The consensus
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23. See Zhang Konglai, Roger Detels, Liao Susu, Myron Cohen, Yu Dongbao, “China HIV/AIDS
epidemic: Continuing challenges,” The Lancet, 20 October 2008, p. 2, published online
at www.thelancet.com; Wang Xiaoqi, Wu Zunyou, “Factors associated with adherence to
antiretroviral therapy among HIV/AIDS patients in rural China,” AIDS, 2007 n°21, Suppl.
8, pp. S149-156.
24. Zhang Konglai et al., op. cit.
25. Speech on 9 July 2004 entitled “All of society must mobilise to prevent and control AIDS
effectively.”
26. “Program on Middle and Long Term Prevention and Controlling of AIDS in China (1998-
2010)” and “Action Program on Prevention and Treatment of AIDS in China (2001-
2005).” We should recall that this was also the period when ARV treatments were intro-
duced and became widespread in clinical practice at a global level.
27. “Clinical Technical Project of AIDS Treatment with TCM”; “Management Project of Trial
Items in AIDS Treatment by TCM”; “Details of Clinical Technical Project on AIDS Treat-
ment by TCM in Five Provinces (Henan, Hebei, Anhui, Hubei, Guangdong)”; “Recommen-
dation on Guidelines of Diagnosis and Treatment of AIDS’’; “Clinical Technical Project on
AIDS Treatment with TCM”; cf. Wu Gang, “Status and Prospect in Preventing and Treat-
ing HIV/AIDS with Traditional Chinese Medicine,” Chinese Journal of Integrative Medicine
(Zhongguo jiehe yixue zazhi), 2006, vol. 12, n°2, pp. 81-84, English language edition.
28. We should recall that Chinese medicine was introduced into Tanzania in the 1970s thanks
to the close links established between the Chinese and Tanzanian governments. Chinese
medical teams were sent by the central and provincial governments to work in the coun-
try’s district hospitals. Cf. Elisabeth Hsu, 2002, “‘The medicine from China has rapid effects‘:
Chinese medicine patients in Tanzania,” Anthropology&Medicine, vol. 9, n°3, pp. 291-313.
29. A (non-exhaustive) summary of the protocols, hypotheses, and results of research car-
ried out in the 1990s is provided in Lu Weibo, Traitement du sida par la médecine et la
pharmacopée traditionnelles chinoises: Huit cas de conversion séronégative, translated
from the Chinese by Mo Xuqiang, Paris, Quimétao, 1998, 127 pp. Lu also refers to re-
search carried out in China and its results published in Chinese journals such as zhongyi
zazhi (TCM Journal), Zhongyi xueyuan xuebao (TCM Institute review), Zhongyiyao xue-
bao (TCM pharmacopeia review), Zhongguo zhongxiyi jiehe zazhi (Chinese journal of in-
tegrated traditional and Western medicine); further information and clinical tests are re-
ported in Zhong Dajin, Wang Xuao, Zhao Shuzhen, Fu Lining (compilers), Aizibing de
zhongyi zhiliao (Treatment of AIDS with TCM), Beijing, Zhongguo Shandong kexue jishu
chubanshe (Shandong Science and Technology Press), 1992, 127 pp.
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among researchers today is that methodological shortcom-
ings produced biases and led to highly questionable results
such as cases of “negative seroconversion.” (30)
Official discourse on the subject highlights three stages in
the research in progress over the past 20 years and its clini-
cal application to HIV treatment: the exploratory stage in
Tanzania (1987-1995) consisted of acquiring general knowl-
edge and building up clinical tests; the stage of preliminary
research (1995-2003) was characterised by observations
made possible by the TCM treatment of patients in areas
where the epidemic had developed in China; simultane-
ously, medicinal plants were tested in laboratories and se-
lected for their anti-HIV effects. Lastly, since 2003, the
third stage has centred around the standardisation of the
products identified and their development for possible mar-
keting. (31)
We should note, however, that the ethical problems raised
by this research have rarely if ever been mentioned up to
now. This situation is worrying, as the first two stages, one
delocalised to Africa and the other relocalised to China, ap-
parently prolonged while waiting for the introduction of a na-
tional programme in certain regions and localities, imply the
treatment of under-informed patients, first by monotherapy
with AZT for the treatment of HIV after 1994, and then by
multitherapies introduced in 1996. In fact, access to ARVs
was limited to patients who could afford them, because there
was no reimbursement before the launch of the national pro-
gramme in the context of the public health system.
C ombin ed/ comp lement ary  trea tment :S ome fr ag men ta ry  bu t  mean in gfu l  d ata
We note a time lag between the political determination
stated for two decades and the progress of research toward
widespread application of a product in everyday clinical
practice. This situation has not yet come about in reality, but
is in pilot clinical or everyday practice, depending on the lo-
cality, with the introduction of the Tang herbal tablet, which
was finally approved for the treatment of HIV infection in
2006 by the SFDA (32) and is today recommended at the na-
tional level as a complementary treatment with HAART.
This recommendation is not unanimously approved among
healthcare workers and administrative cadres in the health
system, however. For example, in Number 4 Hospital in
Nanning, where the Tang tablet is prescribed in accordance
with the recommendation, some members of the AIDS, In-
fectious Disease and Hepatitis Department, and some hos-
pital cadres, say it will take some time to confirm the effec-
tiveness of the herbal tablet. To them and to other members
of the medical staff, TCM products cannot be validated by
clinical trials as in biomedicine, but only by “old-fashioned”
clinical experience, according to which effectiveness can
only be confirmed over a long period of time, stretching over
generations. At the MSF clinic in Nanning, which cooper-
ates with this hospital, members of the medical staff believe
that the product can’t do any harm, but its use was not pro-
moted because TCM products have a certain cost, and the
association could not pay for medicine that is not certified at
an international level. (33) In Guangzhou, at the Number 8
Hospital that has an AIDS department, collaboration is
closer between the medical, TCM research, and biomedi-
cine staff because a TCM dispensary operates within the
department, combining everyday clinical practice with re-
search carried out with the traditional medical University.
Around ten beds are reserved for patients volunteering for
joint treatment, and patients being treated at Number 8
Hospital were recruited for a test being carried out at the tra-
ditional medicine university. An interesting but very worry-
ing aspect of the test underway is the number of drop-
outs, (34) which repeatedly reached 30 percent, since the
number of other patients newly included equalled that of
those who “left” the research protocol. (35)
Lastly, returning to a macrosocial rather than a microsocial
analytical perspective, we should note that beyond the polit-
ically correct discourse heard in certain meetings, the share
represented by TCM in China CIPRA (China Compre-
hensive Integrated Programs for Research on AIDS) proj-
ects and their publications is limited. (36) Moreover, TCM
was referred to in a UNAIDS report for the first time in
2007, in a section dealing with the treatment of opportunist
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30. Title of Lu Weibo’s book, op. cit.
31. Wu Gang, art.cit., p.83.
32. We should nevertheless mention that in 2006 this national organisation was implicated
in a series of serious scandals concerning the health safety of food and medicinal prod-
ucts, events widely reported in the official Chinese press by Xinhua, China Daily, etc.,
and internationally by Reuters, among others. These scandals undermined its authority
and led to severe penal sanctions, including the execution of the organisation’s former
head in July 2007.
33. Interviews and observation carried out during field research in January 2008: visits to
Number 4 Hospital and to the MSF clinic in Nanning.
34. In the framework of the HAART-TCM programme: some patients rejoined the non-com-
bined HAART programme.
35. Id.: visits to the departments and research laboratories in Number 8 Hospital and to the
traditional medicine university.
36. See China CIPRA Reference book, China CIPRA Overview, 2007, 253 pp., and China
CIPRA’s Publications Book, 2007, 340 pp., published by China CIPRA, www.cipran-
caids.org.cn. The CIPRA programmes implemented at a global level, an initiative sup-
ported by the US NIH (National Institutes of Health), are part of the world research
agenda of NIAID (National Institute of Allergy and Infectious Diseases) established in re-
sponse to the global HIV/AIDS epidemic.
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illnesses: “The treatment project has been extended to fif-
teen provinces where over 6,000 patients receive it. Under
treatment, the condition of patients has improved and some
have been able to resume their professional activity.“ (37) The
national pilot project on the use of TCM for the treatment
of HIV/AIDS implemented in Guangxi and Yunnan begin-
ning in 2005 shows encouraging results, with a reduction in
clinical symptoms, a better quality of life, and no side effects
or unfavourable reaction reported in the local press. (38)
Moreover, an example of the use of the pharmacopoeia
aimed at preventing the transmission of HIV through the
sharing of contaminated needles by intravenous drug users,
which remains a common means of transmission (after being
the dominant means of transmission until 2005), was re-
ported in 2008. The formula being tested can help end drug
use: “It has particular properties which fight psychological
addiction and anxiety, and prevent relapse.” (39)Res ea r ch i n  tr a dit io nalme dic ine  a nd tr e at me nts  forHIV /AI DS
In the first part of this section, I will deal with social and eco-
nomic usages, including aspects of economics and the philos-
ophy of knowledge. The second deals more specifically with
the methodology of clinical testing as well as with treatments
and research into AIDS. The last part, which refocuses on
the Chinese world after a look at international research,
seeks to provide information on tests of treatment for AIDS
in China.
Th e s oc ial,  econ o mi c a nd  sc ien tif ic  u s agesof  T CM in  Ch in a
I will briefly summarise the socio-cultural and economic con-
text of the use of TCM in China today. Chinese medicine
is one of the icons of Chinese identity. For some time, it has
been widely used by the authorities in the context of a more
widespread revitalisation of certain aspects of Chinese cul-
ture, such as the reassertion of the value of the architectural
and artistic heritage, and of an education based on “Confu-
cian” values dispensed by the Confucius Institutes. (40) These
phenomena of “heritage-isation“ and revitalisation of ele-
ments in the cultural repertoire have been identified in many
societies, and are always associated with social change. In
this context one can speak of a tendency to heritage-ise med-
ical knowledge — the problem is determining which knowl-
edge — that is expressed in a diffuse or affirmed manner in
Chinese society today. Concern for the “medical tradition”
has manifested itself in the desire of some categories of the
population, who are witnessing this trend towards the “bio-
medicalisation” of Chinese medicine particularly in research
methods, to remove TCM from the Chinese public health
system and to question the idea of integration (jiehe yixue,
yiliao) and synthesis (zonghe yixue, yiliao) of medicines.
However, we should recall that “integrative” or “hybrid”
practices and knowledge have developed since the 1950s,
particularly during the time of the Cultural Revolution
(1966-1976) in China, supported by a strong political deter-
mination that shaped a consciously formulated hybridisation
and a “top down” syncretism. (41) In an accepted sense that
has been widened to include other socio-cultural contexts
and other forms of medical knowledge, they are also devel-
oping rapidly, and have been validated at an international
level with recommendations and declarations of the WHO
favouring the insertion of TCM in national health systems
since 1980.
To return to the concern for Chinese medicine reflected in
popular rather than official discourse, it is worth noting a de-
bate that reached an unexpected scale at the end of 2006
following the online publication of an article by Professor
Zhang Kongyao, a science philosopher at Hunan’s Univer-
sity of Changsha, which he posted on his blog, and in which
he questioned the insertion of Chinese medicine into the
public health system. The question at the heart of the de-
bate turns out to be much more subtle than the a priori
Manichean one of “for or against” TCM in public medicine
or in general that resulted from distortion of the issue
through media dissemination. Zhang did not radically op-
pose zhongyi, but called into question the process of institu-
tionalisation of this medicine in the framework of schools, in-
stitutes, and universities that teach Chinese medicine
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37. A Joint Assessment of HIV/AIDS Prevention, Treatment and Care in China (2007), State
Council AIDS Working Committee Office, UN Theme Group on AIDS in China, 1 Decem-
ber 2007, 38 pp., p. 25.
38. Chen Yihua, Wei Yishan, Jiang Xian, “Many benefits to treating HIV/AIDS with Traditional
Chinese Medicine,” Nanning Evening News, 18 December 2007; Cai Xiangrong, “1,658
AIDS patients in Yunnan receive free treatment with Chinese Medicine,” Xinhua, 28 Sep-
tember 2007.
39. “Specialized Chinese medicine shows quick results for quitting drugs,” 2 January 2008,
http://nb.qianlong/htlm/news/20081/73379.htm, posted on the site of the NGO
www.china-aids.org, visited on 15 January 2009.
40. For an analysis of references to Confucianism and to “cultural tradition” in official dis-
course in the 2000s, see Sébastien Billioud, “Confucianism, ‘Cultural Tradition,’ and Of-
ficial Discourse in China at the Start of the New Century,” China Perspectives, 2007, n°3,
pp. 50-65.
41. Cf. Sydney D. Whyte, “Deciphering ‘integrated Chinese and Western Medicine’ in the
rural Lijiang basin: State policy and local practice(s) in socialist China,” Social Sciences
and Medicine, 1999, n°49, pp. 1333-1347.
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(zhongyi xuexiao, xueyuan, daxue). (42) In his view, zhongyi
cannot become a discipline in the academic system because
traditional medicine is characterised by its holistic dimension
and its historic, philosophical, and philological links with lit-
erature, poetry, and painting: for example, some prescrip-
tions were calligraphed poems. (43) Zhang suggested returning
TCM to the domain of “popular remedies” (minjian yiliao)
and reasserting its value through hereditary family or spiri-
tual (44) transmission and practice exercised in the framework
of “popular” social organisations (minjian hui/pai), a means
of shedding light on the futility of questions about moderni-
sation and the construction of the evidence according to the
norms of the biomedical sciences. (45)
Moreover, in these times of economic and cultural globalisa-
tion, Chinese remedies appeal to the new middle class in
China and already make up an important part of the global
market for complementary and alternative medicines, and
are thus potentially lucrative. (46) We can therefore hypothe-
sise that traditional medicine in its widest sense is, at the in-
ternational level, the most commonly used repertoire of ther-
apies among non-biomedical medicines.
In the economic sphere, TCM research and development
lies within the framework of the world health market be-
cause of the potential marketing of pharmacotherapy
(zhongyiyao) and traditional pharmacology (zhongyiyao
xue) products. These products could become a welcome
niche market for the Chinese pharmaceutical industry (47) in
the wake of constraints linked to China’s access to the
WTO, (48) when these companies can no longer systemati-
cally manufacture the generic versions of biomedical prod-
ucts patented in the developed countries that previously
made up 97 percent of their production. The development
of TCM pharmacology shows an orientation towards the
merchandising underway in consumer societies by partici-
pating in globalised methods of promoting traditional med-
icines: the marketing methods and packaging of TCM
products are becoming increasingly similar to those origi-
nally used in the United States for dietary supplements (vi-
tamins, anti-oxidants, etc.) and which subsequently spread
worldwide, including a number of products and prepara-
tions that are available without a prescription (over the
counter, or OTC). (49) In her research into the factors that
led African peoples and governments to adopt Chinese
medicine in the 1990s, Elisabeth Sue has emphasised that
economic factors could not be underestimated, even
though other factors such as the socialist orientation of po-
litical ideology, the upward social mobility of patients, and
the treatment strategies of actors attracted to this medicine
out of curiosity or as a last resort, also play a part in the
spread of TCM. (50)
We have noted that while present at negotiations on the de-
velopment of international research in Chinese medicine,
the strategy of China’s industry and the authorities — the in-
dustry being mainly controlled by the State — was to obtain
a licence to sell in developed countries by registering the
compositions of the pharmacopoeia in the medical rather
than dietary supplements category. The legal scientific vali-
dation framework is much more constraining, implying a re-
sort to the EBM (51) model and the carrying out of conclu-
sive (52) (which is not to say successful) clinical tests. Besides
the objective of validation and recognition of a “medical tra-
dition” by the process of “scientific” legitimisation of Chi-
nese medicine, there seems to be a primarily profit-seeking
aim.
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42. On schools, university TCM curricula, the administrative organisation of studies, and the
content of teaching, see Elisabeth Hsu, op. cit., 1999; Eric Marié, “Mutations et enjeux
d’un système médical traditionnel confronté à la modernité,” Monde chinois, 2005,
n°5, pp. 101-124.
43. Joseph S. Wu, “Understanding Chinese Medicine: A Philosophical and Cultural Ap-
proach,” Asian Thought and Society, 1998, vol. 23, n°68, pp. 123-129, p. 125.
44. From master to disciple, training by a lao zhongyishi, a traditional doctor respected be-
cause he is recognised as competent.
45. Cf. Evelyne Micollier, “Transformations de la médecine chinoise en Chine: recherche et
développement, circulation des savoirs et des pratiques,” session “Les médecines
d’Asie aujourd’hui. Trans-nationalisation des pratiques et relocalisation des savoirs,”
Conference of the Asia Network (Rasiem), conference paper, 26-28 September 2007
Paris, 10 pp., accessible online at www.reseau-asie.com.
46. Elisabeth Hsu, “La médecine chinoise traditionnelle en République populaire de Chine,“
with Anne Cheng, La pensée en Chine aujourd’hui, Paris, Gallimard, 2007, 478 pp., pp.
214-238, pp. 237-238.
47. This is still largely in the public sector, although it is undergoing gradual privatisation.
48. December 2001.
49. For examples of alternative treatments for AIDS in Asia and Africa, see Anita Hardon, Alice
Desclaux, Marc Egrot, Emmanuelle Simon, Evelyne Micollier, Margaret Kyakula, “Alterna-
tive medicines for AIDS in resource-poor settings: Insights from exploratory anthropolog-
ical studies in Asia and Africa,” Journal of Ethnobiology and Ethnomedicine, 2008, n°4,
16 pp.; Elisabeth Hsu, “Medicine as Business: Chinese Medicine in Tanzania,” in Chris
Alden, Daniel Large, and Ricardo Soares de Oliveira (eds), China returns to Africa: A Ris-
ing Power and a Continent Embrace, London, Hurst, 2008, 400 pp., pp. 221-235.
50. Elisabeth Hsu, op. cit., 2002, p. 310; for insight into the point of view of international re-
lations on South-South globalisation of Chinese medicine, with the case study of Tanza-
nia, see Michael Jennings, “Chinese Medicine and Medical Pluralism in Dar es Salaam:
Globalisation or Glocalisation?”, International Relations, 2005, vol. 19, n°4, pp. 457-473.
51. EBM “Evidence Based Medicine,” see following note. We should add that this model of scien-
tific validation tends towards an increased rationalisation of medical practices and produces
a regulatory medicine at the expense of a clinical medicine. Cf. Alberto Cambrosio, “Rational-
isation et médecine des preuves en oncologie: quelques remarques à propos de la régulation
des pratiques biomédicales,” Sciences Sociales et Santé, 2005, vol. 23, n°4, pp. 41-48.
52. A particular stage in a set of procedures aimed at demonstrating the harmlessness and
therapeutic effectiveness of a substance, composition, or biotechnology being tested as
a potential therapeutic medicine or technique: it is one of the stages in the development
of a medicine. Clinical trials are an integral part of what is called Evidence Based Med-
icine, the final strictly regulated outcome of “clinical science.” See Philippe Pignarre, Le
grand secret de l’industrie pharmaceutique, Paris, La Découverte, 2004, 199 pp., p. 58.
For a history and an anthropological analysis of clinical trials, cf. Harry Marks, Evidence
Based Medicine History and Anthropology of Clinical Trials (1900-1990).
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Among many ongoing and future research projects, the
Herbalome project, which is large-scale and long-term (15
years), is due to be launched soon. Its objective is the close
examination of TCM products, and the methods used in-
clude high level screening, toxicity tests, and clinical trials to
identify the active substances and toxic substances in
400,000 TCM compositions and 10,000 vegetable and ani-
mal extracts. (53) Moreover, TCM/Chinese medicine appears
in a call for projects launched by the French NRA (National
Research Agency) for the first time this year, following
Franco-Chinese research agreements in partnership with bi-
ological and medical sciences in the Biotechnologies for
Health Programme (54): “The BiotechS programme is open-
ing up internationally in 2009 with the possible participation
of Chinese partners in projects dealing with the study of tra-
ditional Chinese medicines. These international projects will
be evaluated according to the same procedures and by the
same committees as French projects.” Key words in the pro-
gramme include biomarkers, biomaterials, sifting, clinical tri-
als, immunotherapy, non-medical imagery, and therapeutic
innovation. In short, they refer to biotechnologies based on
innovative scientific concepts that exploit cutting-edge tech-
nologies in biology and medicine.
Clin ic al  tri als  an d tr eatmen ts  f or  AID S
Consensually at the level of concepts and practice, clinical
trials are ideally carried out in four stages. Stage I tests and
determines the dose that triggers the initial desired and un-
desired pharmacological effects, usually on healthy subjects
numbering 20 at most. During Phase II, pharmacological ef-
fectiveness is evaluated with the establishment of optimal
dosage and efficient posology. The therapeutic index deter-
mines the relation between the prescribed dose and the toxic
dose. This stage still poses unresolved problems to re-
searchers, and difficulty varies according to the pathology.
Phase III consists of applying a particular methodology
based on comparisons between homogenous groups of pa-
tients, with one receiving the product and the other a refer-
ence product or a placebo. In order for both groups to be
identical, a draw is carried out called randomisation. In
order to prevent an induction phenomenon, the test is car-
ried out “double blind”: none of those concerned knows the
result of the randomisation. Inclusion criteria for patients,
who range in number from 100 to several thousand, are very
precise and selective. This methodology defines double-
blinded randomised and placebo-controlled clinical trials.
Phase IV, known as “pharmacovigilance,“ consists of testing
the effectiveness and tolerance to the product in normal pre-
scription conditions, and in ordinary clinical practice.
I have briefly described the complete methodology of a “nor-
malised” test employed by the scientific community and
pharmaceutical industry as a condition for licensing a medi-
cine for sale in order to give an idea of the complexity of the
process of researching and developing a medicine or biotech-
nology for therapeutic use, from the identification of a sub-
stance, composition, or molecule to the marketing of the
final product.
To continue this analysis with a more specific case study, we
should note that medical research, which ideally tends to-
wards “normalisation” according to the EBM model, has
shown potential but no really significant progress in treat-
ments for HIV/AIDS using natural products. After a
decade of extensive research aimed at discovering natural
anti-HIV agents, a certain number of natural products have
been selected for their specific actions and their low toxicity.
Most of them have the potential to interfere with successive
anti-viral targets, which can produce action mechanisms that
complement those of available anti-viral medicines. How-
ever, the other aspect of the problem concerns the inade-
quately explored interactions between natural anti-HIV
products and biomedical treatments, which in some cases
can make the treatments ineffective or harmful. (55)
In 2005, although no plant-based medicine was currently
being used in clinical practice for treating AIDS, a certain
number of natural plant-based preparations were identified
as potentially anti-viral and were tested in a clinical trial
framework. (56) In 2000, a review of the literature on the re-
sults of the treatment of HIV/AIDS with Chinese medicine
— acupuncture and pharmacopoeia — concluded that despite
promising indications of the reduction of certain symptoms,
the published results were not convincing and showed
methodological weaknesses. (57) At that time it was possible
to identify two kinds of studies: one focused on symptomatic
relief, for example of diarrhoea and neuropathy, while the
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53. “TCM under the microscope: Researchers hope the project will lead to better quality
control,” Science, 12 February 2008.
54. ht tp : / /www.agence-na t iona le-recherche. f r /AAPPro je tsOuver ts?NodId=
17&lngAAPId=227, page visited on 15 January 2009, pdf programme, p. 83.
55. See Edward Mills, Victor Montori, Dan Perri, Elizabeth Phillips, Gideon Koren, “Natural
health product-HIV drug interactions: A systematic review,” International Journal of STD
and AIDS, 2005, n°16, pp. 181-186.
56. See an overview of the situation, including a review of publications, by Inder Pal Singh,
Sandip B. Bharate, K.K. Bhutani, “Anti-HIV natural products,” Current Science, 2005, vol.
89, n°2, pp. 269-290.
57. Acupuncture Research Resource Center (ed.), “HIV Infection and Traditional Chinese
Medicine: The evidence for effectiveness,” Briefing Paper n°6, British Acupuncture
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other explored the use of Chinese medicine in combination
with ARV treatments to alleviate side effects and optimise
the effective treatment. Controlled clinical trials attesting to
the effectiveness of Chinese medicine based on biomedical
markers of HIV (58) infection should be carried out in the
framework of future research. (59) At a methodological level,
the objective will be to normalise clinical trials in traditional
medicine according to international biomedical standards.
C l i n i c a l  t r i a l s  o f  A I D S  t r e a t m e n t s  i nC h i n a
In the 2000s, following a trend observed in emerging and
developing countries, clinical trials in China have undergone
unprecedented development. We should remember that for
a decade the country has been accelerating along the path
of economic and cultural globalisation, including that of the
world health market. We should note that China has very re-
cently integrated the WHO system for the registration of
clinical trials, (60) and that this procedure allows Chinese data
to be submitted to the WHO research site on the Internet.
The Chinese Register of clinical trials was initiated in 2005,
and in less than two years was recognised as compliant with
the norms. According to Margaret Chan, Director General
of the WHO, the efforts of the Chinese and Indian govern-
ments toward this integration reinforce the international
movement for transparency and distribution of information
from research circles to the public.
In this context, even innovative treatments for AIDS are
tested in traditional medicine and in biomedicine. (61) Thus
the legitimisation process for TCM includes validation based
on the evidence provided by biomedical testing: proof of the
biological effectiveness and harmlessness of a composition
or technique being tested has to be provided according to
EBM evaluation criteria in order for these “AMC” treat-
ments to be validated by the international scientific commu-
nity and given a permit to be sold on the market. (62)
It was in 1985 that the first seropositive person was discov-
ered in China, and in that same year the first clinical trials
of treatment for HIV by the pharmacopoeia were carried
out at the Quan Yin Center in San Francisco by Dr. Misha
Cohen’s team. This team also carried out the first double
blind randomised and placebo-controlled test of a Chinese
pharmacopoeia treatment of the symptoms associated with
HIV, the results of which were published in an international
journal. (63)
According to the results reported in a number of Chinese ac-
ademic publications on clinical trials of AIDS treatments,
TCM research shows advances in the identification of
plants, in the extraction of the most active substances, and in
the testing of medicinal compositions: out of 1,000 species
of plants commonly used in the pharmacopoeia, more than
100 have an anti-viral effect and several dozen inhibit the
spread of HIV. (64) These publications confirm that animal,
vegetable, or mineral extracts can be conceptualised and ul-
timately categorised as medicinal products on the biomedical
model without any explicit reference to TCM theory and
practice.
Compounds of CATCM-II (Zhongyan-2) and CATCM-IV
(Zhongyan-4), both of which are innovative TCM treat-
ments undergoing clinical trials, bear the name of the insti-
tution that tests them: the China Academy of TCM
(Zhongguo zhongyi yanjiuyuan), formerly CACMS
(Zhongguo zhongyi kexueyuan). Testing stages have been
carried out in the framework of the TCM treatment of
HIV/AIDS project, which was implemented with the col-
laboration of 50 Chinese researchers with the Muhimbili
Medical Centre in Tanzania over a period of 17 years. This
project produced an accumulation of clinical trials and the
publication of more than 100 articles. In terms of existing
medicines in development, the Tang herbal tablet has been
approved by the SFDA and can be marketed in China,
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58. Such as the viral charge and the CD4 count: HIV infection triggers a chronic reduction
in T lymphocytes and compromises the normal function of the immune system of those
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59. Acupuncture Research Resource Center (ed.), op. cit.
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61. For examples of biomedicine research in the framework of the development of preven-
tive or therapeutic vaccination research, see Evelyne Micollier, “AIDS medical research,
an exploratory Inquiry,” poster 535, session 26.4, AIDSimpact International Conference,
Marseilles, 1-4 July 2007; for an overview of biomedicine research projects in progress
(in epidemiology, virology, immunology, clinical treatment, and vaccine development) in
the framework of the China CIPRA programmes, see China CIPRA Reference book, op.
cit, 2007, pp. 30-93; Shao Yiming, “HIV/AIDS research in China: Arising up from skyline,”
Chinese Medical Journal, 2006, vol. 119, n°23, pp. 1939-1940.
62. On public policies dealing with the use of CAMs and their validation, see WHO Fact Sheet
271 Traditional and Alternative Medicine, 2002, and “Stratégies de l’OMS pour la
médecine traditionnelle (2002-2005)”; White House Commission on Complementary
and Alternative Medicine Policy, Final Report, Washington D.C., 2002. On the concepts
and evidence of CAMs, cf. Evelyne Micollier, “Experimenting on scientific versus tradi-
tional treatments: The case of AIDS medical research in China,” Proceedings of the In-
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“The role of evidence in alternative medicine: Contrasting biomedical and anthropolog-
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63. Jeffrey H. Burack, Misha R. Cohen, Judith A. Hahn, Donald I. Abrams, “Pilot Randomized
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64. Cf. Wu Gang, art. cit., p. 83.
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while tests of the Qiankunning capsule, the Keaite capsule,
the Chuankezhi injection, the Aining granule, and the San-
huang composition are underway or have been com-
pleted. (65) The SFDA’s functions primarily concern the
safety of food and health products, but also include supervi-
sion of research protocols and clinical trials submitted for the
organisation’s prior approval.
Let us take the example of the publication by Ma et al. (66)
resulting from the clinical trial aimed at testing the effective-
ness of the Aikeqing capsule in treatment combined with
ARVs, in order to shed light on the problem of evaluating
results. The protocol describes a clinical trial that will lack
scientific validity, regardless of its outcome, since its inclu-
sion of only eight patients without a control group does not
meet the international norms for a double blind random trial.
However, some clinicians see the results as showing some
therapeutic effectiveness. This kind of clinical research could
be validated to some extent in a pre-EBM framework. It is
not merely a clinical trial dependent on the subjectivity of
one practitioner. Thus the toxicity of TCM products was tra-
ditionally documented by clinical trial, while the most mod-
ern toxicity data are based on animal testing in the frame-
work of pre-clinical trials. (67)
The initial results of documentary research (68) show that the
most widely-used treatments are commonly used in the daily
lives of people and families to maintain health, stimulate the
immune system, and improve the overall immunity of the
body. A very small number of treatments tested are TCM in-
novations — for example the Zhongyan-1 to Zhongyan-4
compounds.
To give an idea of innovative treatments tested according to
the methodology of random double blind trials with a con-
trol group under placebo, I will give some indications regard-
ing the Zhongyan-4 composition taken from the results pub-
lished by Wang et al. (69) The product tested, prepared by the
Tianjiang Pharmaceutical Company based in Jiangsu, in-
cludes extracts of “Ginseng root, Astragalus root (Radix As-
tragali), Fructus lycii, Radix Fricosanthis, Radix Scutelle-
riae, Herba Vilae, etc.” The article concludes that the
preparation has a function of protection and/or reconstruc-
tion of the immunity of patients with early and intermediate-
stage AIDS infection, contributes to reducing the power of
the virus, increases body weight and improves certain symp-
toms. (70) The first two components mentioned, Ginseng root
and Astragalus root, have a long history in the corpus of the
pharmacopoeia, indicated for immune deficiency with the
main function of stimulating the immune system. Con-
stituents in the second component are the object of research
at an international level that has begun to produce encourag-
ing results reported in an international journal of immunol-
ogy. (71) Moreover, Curcumin, a major constituent of natural
curcuminoids extracted from plants, has an effect against
AIDS, according to another recent publication. (72)
We should note that the treatments tested in the framework
of clinical trials are usually pharmacopoeia (zhongyao) com-
positions and prescriptions, possibly accompanied by a com-
plementary treatment (zhenjiu, qigong), although acupunc-
ture-moxibustion and qigong treatments are described, for
example, in Song et al. (73) I was struck, moreover, by the in-
terest shown by one of my interlocutors, D., the deputy di-
rector of the research institute concerned, in qigong treat-
ments, the use of which has always been more or less called
into question by health professionals and authorities in the
institutional framework. All the same, D. believed that he
was not yet sufficiently qualified to treat or begin research on
the treatment of AIDS by qigong. (74)
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It is clear, therefore, that a number of obstacles remain on
the path of marketing traditional products and practices.C onclus ion
The results of clinical trials of TCM AIDS treatments do
not for the moment reveal any significant advance as recog-
nised by the international scientific community, even if some
international-level publications report encouraging results. In
China, a single product, the Tang herbal tablet, has been li-
censed for the market, and its use is now recommended in
the clinical practice of combined treatments. As has been
stated by Cao Yunzhen, immunologist and head investigator
of the axis concerned with clinical research into AIDS on
the China CIPRA programme, no specific category of med-
icine has been identified as inhibiting the spread of the virus
and rebuilding the patient’s immunity. (75) Having said that,
the use of TCM in treatments, follow-up, and research has
an important place in Chinese public health policies. The
role given to contemporary TCM, reinforced by its place as
a knowledge established as an icon of national identity, is un-
derpinned by the validation and legitimisation of a combined
scientific and traditional rationality. As I have sought to
demonstrate in this article, this legitimisation tends to be
based on the EBM model, thus reflecting a current tendency
in biomedical research, as well as on an invented or rein-
vented model of knowledge drawn from the source of Chi-
nese cultural heritage.
In this context, the use of TCM in AIDS treatment is pro-
moted in the framework of national management of the epi-
demic. This role can also be explained by more pragmatic
factors: the unresolved problems previously mentioned here,
which affect the extension of treatment and follow-up, in-
cluding what is still very limited access to second-line ARV
treatment regimes, as well as, from an economic perspective,
the urgent need for innovation in order to survive in the face
of international competition in the Chinese pharmaceutical
industry sector, can also be factors that explain the official
position vis-à-vis traditional medicine. Since 2004, ARV
treatment regimes provided free of charge in the framework
of the national programme have been the object of discus-
sion and sharp criticism reflecting conflicts of interest be-
tween various categories of national/global, economic, and
political actors. (76) In fact, in China today, access to second-
line treatments is still limited to the framework of pilot
schemes, and while first-line treatments remain more eco-
nomical, they do not offer the best combinations, particu-
larly because they are associated with the development of re-
sistance and generate particularly strong side effects, a fact
that tends to encourage the abandonment of treatment and
non-observant behaviours. These inconveniences or defi-
ciencies, inherent in the prescribed medicinal regimes, can
facilitate the acceptance of traditional medicine by patients
as integrative treatment and even as an alternative treatment.
In an oral presentation at the WHO Conference on tradi-
tional medicines (7-9 November 2008), Deputy Health
Minister and Director of the SATCM, Wang Guoqiang, re-
ferred to the use of TCM only as a treatment complemen-
tary to or combined with the HAART programme, and
reaffirmed the principles inscribed in the national pro-
gramme for the prevention, treatment, and follow-up of
AIDS, which recommends prescribing TCM in a manner
“integrated” with biomedical treatments as an asset available
in the national culture to be developed in fundamental and
applied research.
Nevertheless, given that TCM treatments and research are
not yet standardised, and that interactions between biomed-
ical and traditional medicines are not sufficiently docu-
mented, the use of TCM in combined treatments generates
strong controversy in the world of clinical practice and re-
search, public health, and health administration. From the
patients’ point of view, popular perception can differ from
that of health professionals, and depart from a scientific ra-
tionality that values only experimental proof while ignoring
the existence of other rationalities. Within the Chinese
world, in Hong Kong, which enjoys special status in the
People’s Republic, and where over 95 percent of the popu-
lation is Chinese, Chinese medicine is typically considered
a complementary follow-up to Western medicine. (77) Accord-
ing to a recent study, use of TCM does not seem to have sig-
nificant influence on HAART regimes among the popula-
tion concerned; (78) the majority of patients consume tradi-
tional products following a reasonable time interval after tak-
ing ARV, in order not to reduce its effectiveness. The dis-
cussion concerning the use of traditional medicine in China
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needs to be widened to its validated use outside China in
schemes to treat HIV/AIDS and other chronic illnesses
such as cancer, particularly in pain relief and in palliative
treatments. In the context of cultural globalisation, while cer-
tain elements are becoming more homogenous, an addi-
tional process of hybridisation on a structural and/or contex-
tual fluctuation level is being produced through the normal
flow of events. (79) •
• Translated by Michael Black
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p. 85.
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Glossary
guojia shipin yaopin jiandu guanliju
國家 食品 藥品 監督 管理局
guojia zhongyiyao guanliju 國家 中醫藥 管理局
simian yi guanhuai 四免 一 關懷
zhongyi 中醫
xiyi 西醫
zonghe yiliao 綜合 醫療
jiehe yixue 結合 醫學
zhenjiu 針灸
qigong 氣功
zhongyao 中藥
Zhongyan-4 中研-4號
Qiankunning 乾坤寧
Aining 艾寧
Keaite 克艾特
Chuankezhi 喘可治
Aikeqing 艾可清
Tangcao 唐草
Sanhuang 三黃
minjian yiliao 民間 醫療
minjian hui/pai 民間 會/派
aizibing liaofa zhongxin 艾滋病 療法 中心
Zhongguo zhongyi yanjiuyuan 中國 中醫 研究院 
Zhongguo zhongyi kexueyuan 中國 中醫 科學院 
Zhongguo jiehe yixue zazhi 中國 結合 醫學 雜誌 
fangyi ju 防疫局
weisheng ju 衛生局
